Tg Therapeutics (TGTX) Non-Current Deferred Tax Liability (2022 - 2024)
Tg Therapeutics (TGTX) posted quarterly Non-Current Deferred Tax Liability of $6.2 million for Q4 2024, down 89.97% year-over-year from $61.8 million in Q1 2024, and down 89.97% quarter-over-quarter from $61.8 million in Q4 2023.
Tg Therapeutics (TGTX) Non-Current Deferred Tax Liability (2022 - 2024) Analysis & Trends
Tg Therapeutics' Non-Current Deferred Tax Liability history runs 3 years deep, the most recent figure standing at $6.2 million for Q4 2024.
- In Q4 2024, Non-Current Deferred Tax Liability fell 89.97% year-over-year to $6.2 million; the TTM figure through Dec 2024 stood at $6.2 million (down 89.97% YoY), while the FY2024 annual figure was $6.2 million, down 89.97% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2024 stood at $6.2 million, down from $61.8 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $61.8 million in Q4 2023, with the low at $6.2 million in Q4 2024.
- The 3-year median for Non-Current Deferred Tax Liability is $38.5 million (2022), against an average of $35.5 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability jumped 60.52% in 2023, then slumped 89.97% in 2024.
- Tg Therapeutics' Non-Current Deferred Tax Liability stood at $38.5 million in 2022, then surged by 60.52% to $61.8 million in 2023, then plunged by 89.97% to $6.2 million in 2024.
- Business Quant data shows TGTX's Non-Current Deferred Tax Liability at $6.2 million in Q4 2024, $61.8 million in Q4 2023, and $38.5 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 6.20 Mn |
| Dec 31, 2024 | 6.20 Mn |
| Dec 31, 2023 | 61.80 Mn |
| Dec 31, 2023 | 61.80 Mn |
| Dec 31, 2022 | 38.50 Mn |
| Dec 31, 2022 | 38.50 Mn |